JUVENESCENCE appoints Dr Richard Marshall CBE as Chief Executive Officer

RAMSEY, Isle of Man–(BUSINESS WIRE)–Juvenescence has appointed Dr. Richard Marshall CBE as its new CEO, effective January 16, 2023. Marshall succeeds co-founder Gregory Bailey, MD, who will remain on the company’s board of directors as executive chairman.

dr. Marshall brings more than twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis and Lung Injury Detection Unit (DPU). Most recently, Dr. Marshall was Senior Vice President, Head of Global Development, Respiratory and Immunology for AstraZeneca. dr. Marshall was awarded a CBE in the Queen’s Honors List in 2021 for his contribution to science in the UK and the COVID-19 disease.

“I am delighted that Dr. Richard Marshall CBE, former Senior Vice President, Global Head of Development, Respiratory and Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative research and development strategies to drive innovation and achieve rapid growth, with experience in collegial success, building high-performing teams and developing novel therapies.”, outgoing CEO Dr. Gregory Bailey He said. “Richard is a results-driven leader who believes that in a post-Covid-19 world facing an impending crisis of inverted demographic pyramids coupled with under-capitalized pension funds and rising healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a key player in the mega-trends now moving towards healthier lifestyles and the digital health strategies needed to address these issues. With this appointment, I am confident that we have a world-class team with the experience and skills to position Juvenescence as one of the leading biotech and pharmaceutical companies focused on modifying aging through prevention.

Dr Richard Marshall CBE He said, “I am delighted to be joining Juvenescence at such a pivotal time in the company’s history. They are at a real turning point, with an incredible opportunity to build on Juvenescence’s trusted brand and the founder’s 30-year history of drug development to bring to market innovative approaches to modify and prevent the effects of aging. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the key capabilities needed to succeed in this rapidly evolving field. I look forward to working with the team, our partners and shareholders to take advantage of this incredible opportunity.

About Juvenescence

Juvenescence is a life science company developing therapies to reverse aging and extend healthy lifespans. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers and investors with a significant track record of success in pharmaceutical drug development, synthetic biology and tissue and cell engineering.

Juvenescence has a broad portfolio of products in development and drives innovation, with a focus on the discovery and development of these therapies to modify the aging process, prevent and regenerate damage, to support healthy aging and extend lifespan. The company is committed to inspiring and equipping the world to not only reinvent what it means to age, but also to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com

Leave a Reply

Your email address will not be published. Required fields are marked *